Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PinnacleXon Oct 11, 2019 10:38am
99 Views
Post# 30221761

RE:Weekly Sales Update

RE:Weekly Sales Update
SPCEO1 wrote: Trogarzo had a pretty good week of sales int he most recent Bloomberg report, making it 3 of the last 4 weeks with nice sales numbers. More typically, it is two weeks higher and two weeks lower. Now, we know these numebrs are also far less than precise indicators of actual sales with Bloomberg being too low by about 14% in Q1, to low by about 4% in Q2 and too high by about 14% in Q3..Since we now know that the new patients number Bloomberg reports is a mixture of new patients and older patietns refilling their prescriptions, I will just not bother reporting that infoa is not helpful.

Egrifta sales were on the low end for the last week. With the sales force having been trained to sell the new version of Egrifta very recently, you have to wnder if they are not pushing the old version quite as hard. Or perhaps, the lwoer sales numebr reflects only that they were in training part of that week and thus not on the road visiting clinics and doctors offices.

I think there may be some confusion on the board about the advertising efforts.It sounds to me that print advertising is ceasing and the focus in going to be exclusively on social media, where they did see some favorable results. That likely means a lot of Facebook advertising given the success that many firms have had in using Facebook to improve sales. So, I believe it is only social media advertising that will be rolled out to ten cities. I suspect this campaign has a better chance of reaching potential Egrifta patients since there are just not as many Trogarzo patients to target, so that may be where the company focuses its advertising dollars. I also wonder if they will delay any new advertising efforts for Egrifta until the new version is available.    


Haha back to you and that fake Bloomberg numbers, I guess you just cant fix the nut in you unreal, you'll still post fake numbers when you know they aren't right never were never will be.
Bullboard Posts